Physician

Ana Maria Lamas, M.D.

According to 2025 Medicare claims, Ana Lamas, M.D. (NPI: 1063418606) practices allergy/immunology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is VITALMD GROUP HOLDING LLC (NPI: 1871572032; TIN: 542129332) and primary practice location at 33145-2546. Lamas is affiliated with the The Accountable Care Organization, Ltd. (ACO ID: A2098), participating under the MSSP model.

Lamas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 151 traditional Medicare patients, billed 6,615 HCPCS/CPT codes, and received $60,952 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 701 prescription claims across 145 beneficiaries totaling $193,745 in drug costs, led by Nucala (Mepolizumab). DME data shows 106 claims. Open Payments data shows 26 records totaling $558. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $136,282 to $60,952. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $136,202 to $193,745. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $1,995 to $310.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	225	14,388	$136,282
2016	201	13,054	$126,542
2017	196	11,881	$110,747
2018	224	13,394	$132,066
2019	184	14,237	$130,982
2020	141	9,147	$87,462
2021	163	9,038	$92,321
2022	167	8,536	$85,552
2023	153	7,127	$67,604
2024	151	6,615	$60,952

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	271	1,546	$136,202
2016	223	1,313	$130,705
2017	250	1,514	$194,532
2018	341	2,141	$262,801
2019	341	2,180	$243,407
2020	318	2,196	$318,052
2021	334	1,992	$249,340
2022	332	1,945	$421,603
2023	209	1,269	$376,310
2024	145	701	$193,745

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	30	161	$2,100
2016	15	148	$1,647
2017	12	92	$872
2018	13	101	$19,272
2019	11	169	$94,704
2020	N/R	73	$35,623
2021	N/R	107	$190,337
2022	N/R	69	$129,573
2023	N/R	59	$102,991
2024	N/R	106	$126,647

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	47	62	$87
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	48	48	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	84	124	$60
36415	Insertion of needle into vein for collection of blood sample	45	56	$9
95004	Test for allergy using allergenic extract	41	2,647	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nucala	Mepolizumab	12	336	$129,104
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	780	$16,432
Breo Ellipta	Fluticasone/Vilanterol	17	630	$8,732
Epinephrine	Epinephrine	25	575	$3,929
Azelastine Hcl	Azelastine Hcl	81	4,694	$3,120

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	16	$36,942
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$34,126
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	13	$32,714
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	40	$12,998
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	12	$9,836

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	26	$558	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ana Maria Lamas, M.D.?

Tedicare shows public-source Medicare data for Ana Maria Lamas, M.D. (NPI 1063418606), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ana Maria Lamas, M.D. have ACO affiliation data?

Ana Maria Lamas, M.D. is shown with ACO affiliation data for The Accountable Care Organization, Ltd. (MSSP, ACO ID A2098).

What billing organization is linked to Ana Maria Lamas, M.D.?

Ana Maria Lamas, M.D. is linked to VITALMD GROUP HOLDING LLC (billing NPI 1871572032) in the available physician profile data.

Does Ana Maria Lamas, M.D. have Open Payments data?

Ana Maria Lamas, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.